These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 28138260)

  • 21. Cost-effectiveness analysis of treatment of venous thromboembolism with rivaroxaban compared with combined low molecular weight heparin/vitamin K antagonist.
    Bamber L; Muston D; McLeod E; Guillermin A; Lowin J; Patel R
    Thromb J; 2015; 13():20. PubMed ID: 26074735
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anticoagulation for the long term treatment of venous thromboembolism in patients with cancer.
    Akl EA; Barba M; Rohilla S; Terrenato I; Sperati F; Muti P; Schünemann HJ
    Cochrane Database Syst Rev; 2008 Apr; (2):CD006650. PubMed ID: 18425959
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer.
    Lee AY; Levine MN; Baker RI; Bowden C; Kakkar AK; Prins M; Rickles FR; Julian JA; Haley S; Kovacs MJ; Gent M;
    N Engl J Med; 2003 Jul; 349(2):146-53. PubMed ID: 12853587
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Economic evaluation of the prophylaxis for thromboembolism in critical care trial (E-PROTECT): study protocol for a randomized controlled trial.
    Fowler RA; Mittmann N; Geerts WH; Heels-Ansdell D; Gould MK; Guyatt G; Krahn M; Finfer S; Pinto R; Chan B; Ormanidhi O; Arabi Y; Qushmaq I; Rocha MG; Dodek P; McIntyre L; Hall R; Ferguson ND; Mehta S; Marshall JC; Doig CJ; Muscedere J; Jacka MJ; Klinger JR; Vlahakis N; Orford N; Seppelt I; Skrobik YK; Sud S; Cade JF; Cooper J; Cook D; ;
    Trials; 2014 Dec; 15():502. PubMed ID: 25528663
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dalteparin versus Enoxaparin for the prevention of venous thromboembolic events in trauma patients.
    Okoye OT; Gelbard R; Inaba K; Esparza M; Belzberg H; Talving P; Teixeira PG; Chan LS; Demetriades D
    Eur J Trauma Emerg Surg; 2014 Apr; 40(2):183-9. PubMed ID: 26815899
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-molecular weight heparin versus vitamin K antagonists for the treatment of cancer-associated thrombosis: A cost-effectiveness analysis.
    Connell NT; Abel GA; Connors JM
    Thromb Res; 2017 Feb; 150():53-58. PubMed ID: 28039844
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Apixaban and dalteparin in active malignancy associated venous thromboembolism. The ADAM VTE Trial.
    McBane Ii R; Loprinzi CL; Ashrani A; Perez-Botero J; Leon Ferre RA; Henkin S; Lenz CJ; Le-Rademacher JG; Wysokinski WE
    Thromb Haemost; 2017 Oct; 117(10):1952-1961. PubMed ID: 28837207
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
    Akl EA; Kahale L; Barba M; Neumann I; Labedi N; Terrenato I; Sperati F; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2014 Jul; (7):CD006650. PubMed ID: 25004410
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of apixaban vs low molecular weight heparin/vitamin k antagonist on hospital resource use in patients with venous thromboembolism.
    Browne C; Lanitis T; Hamilton M; Li X; Horbyluk R; Mardekian J; Kongnakorn T; Cohen A
    J Med Econ; 2017 Jan; 20(1):98-106. PubMed ID: 27822962
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rivaroxaban versus enoxaparin/vitamin K antagonist therapy in patients with venous thromboembolism and renal impairment.
    Bauersachs RM; Lensing AW; Prins MH; Kubitza D; Pap ÁF; Decousus H; Beyer-Westendorf J; Prandoni P
    Thromb J; 2014; 12():25. PubMed ID: 25750589
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Effect of a dalteparin prophylaxis protocol using anti-factor Xa concentrations on venous thromboembolism in high-risk trauma patients.
    Droege ME; Mueller EW; Besl KM; Lemmink JA; Kramer EA; Athota KP; Droege CA; Ernst NE; Keegan SP; Lutomski DM; Hanseman DJ; Robinson BR
    J Trauma Acute Care Surg; 2014 Feb; 76(2):450-6. PubMed ID: 24458050
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dabigatran for the Treatment and Secondary Prevention of Venous Thromboembolism; A Cost-Effectiveness Analysis for the Netherlands.
    Stevanović J; de Jong LA; Kappelhoff BS; Dvortsin EP; Voorhaar M; Postma MJ
    PLoS One; 2016; 11(10):e0163550. PubMed ID: 27776137
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2011 Apr; (4):CD006649. PubMed ID: 21491395
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2011 Jun; (6):CD006649. PubMed ID: 21678360
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Total costs of treating venous thromboembolism: implication of different cost perspectives in a Danish setting.
    Nielsen A; Poulsen PB; Dybro L; Kloster B; Lorentzen A; Olsen J; Kümler T
    J Med Econ; 2019 Dec; 22(12):1321-1327. PubMed ID: 31516054
    [No Abstract]   [Full Text] [Related]  

  • 36. The Efficacy and Safety of Rivaroxaban and Dalteparin in the Treatment of Cancer Associated Venous Thrombosis.
    Chaudhury A; Balakrishnan A; Thai C; Holmstrom B; Nanjappa S; Ma Z; Jaglal MV
    Indian J Hematol Blood Transfus; 2018 Jul; 34(3):530-534. PubMed ID: 30127566
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness analysis of apixaban compared to low-molecularweight heparins and vitamin k antagonists for treatment and secondary prevention of venous thromboembolism.
    Elías I; Oyagüez I; Alvarez-Sala LA; García-Bragado F; Navarro A; González P; De Andrés-Nogales F; Soto J
    Farm Hosp; 2016 May; 40(3):187-208. PubMed ID: 27145388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Kahale L; Neumann I; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2014 Jun; (6):CD006649. PubMed ID: 24945634
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness analysis of extended duration anticoagulation with rivaroxaban to prevent recurrent venous thromboembolism.
    Coleman CI; Limone BL; Bookhart BK; Mody SH; Nutescu EA
    Thromb Res; 2014 May; 133(5):743-9. PubMed ID: 24582461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer.
    Akl EA; Vasireddi SR; Gunukula S; Barba M; Sperati F; Terrenato I; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2011 Feb; (2):CD006649. PubMed ID: 21328285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.